. Author manuscript; available in PMC: 2010 Jun 25.

Published in final edited form as: J Clin Psychiatry. 2010 May 4;71(6):707–715. doi: 10.4088/JCP.09m05171bro

Table 4.

Table 4a. CD4 and Log₁₀ Viral Load during Double Blind and Open Treatment Phases: Paired t-tests within groups
		Double Blind Phase				Open Treatment Phase

		Modafinil Group (N = 58)		Placebo Group (N = 44)		12 Weeks on Modafinil (N = 73)
CD4	Week 0	481 (249)	t = 0.85	459 (257)	t = −1.20	Week 0	475 (272)	t = 1.79
CD4	Week 4	466 (244)	p = .40	482 (240)	p = .24	Week 12	444 (223)	p = .08
log₁₀ VL	Week 0	2.53 (1.2)	t = 1.98	2.41 (1.2)	t = 1.05	Week 0	2.53 (1.19)	t = 3.02
log₁₀ VL	Week 4	2.31 (1.0)	p = .052	2.30 (1.1)	p = .300	Week 12	2.20 (0.99)	p = .003

Table 4b. CD4 and Log₁₀ Viral Load at 6 Month Follow-up: Paired t-tests within groups
		On Modafinil 6 Months (N = 47 )		Not on Modafinil (N = 44)
CD4	Week 0	463 (259)	t = 1.04	489 (267)	t = 1.28
CD4	Week 26	438 (181)	p = .303	451 (241)	p = .207
log₁₀ VL	Week 0	2.49 (1.18)	t = 2.85	2.51 (1.23)	t = 0.35
log₁₀ VL	Week 26	2.05 (0.67)	p = .007	2.45 (1.26)	p = .729

Note: No statistically significant differences were found between groups on CD4 and log₁₀ viral load at baseline and week 4.